TMCnet News
Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related VirusesBOTHELL, WA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Sam Lee, Ph.D., President of Cocrystal, will present data from its unique structure-based drug design platform technology at the 26th International Symposium on Hepatitis C Virus and Related Viruses (“HCV2019”) Conference being held October 5-8, 2019 in Seoul, South Korea. The Company's proprietary structure-based drug discovery technology has demonstrated the ability to design and develop a high barrier to drug resistance and to be a highly potent, selective NNI that is active against all HCV genotypes (1-6) with low level cytotoxicity in multiple cell types. The details for the Company’s poster presentation are as follows: Presenting Author: Sam Lee, Ph.D. About the HCV2019 Conference The Annual ‘International Symposium on Hepatitis C Virus and Related Viruses’ started in 1994 for advancement of HCV and related virus research. During the past 25 years, the symposium has contributed to the understanding of the life cycle of HCV and related immune responses, and the development of antiviral drugs, resulting in dramatic improvement in the treatment of hepatitis C. For more information, please visit the conference website. About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. The Company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks. Cocrystal recently entered into an exclusive worldwide license and collaboration agreement with Merck & Co., Inc. to discover and develop certain proprietary influenza A/B antiviral agents. CC-42344, the Company’s molecule for the treatment of influenza A, is currently being evaluated in preclinical IND-enabling studies. In addition, the Company has a pipeline of promising early preclinical programs and continues to identify and develop novel antivirals for the treatment of norovirus gastroenteritis using the Company’s proprietary structure-based drug design technology platform. For further information about Cocrystal, please visit www.cocrystalpharma.com. Forward-Looking Statements Investor and Media Contact: |